I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Epilepsy Research Program

Longitudinal Risk Factors Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-18-ERP-LRFA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), July 26, 2018
- Invitation to Submit an Application: September 6, 2018
- Application Submission Deadline: 11:59 p.m. ET, October 4, 2018
- End of Application Verification Period: 5:00 p.m. ET, October 9, 2018
- Peer Review: December 2018
- Programmatic Review: February 2019

This Program Announcement must be read in conjunction with the General Application Instructions, version 20180312. The General Applications Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ........................................... 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY ............ 3
   II.A. Program Description ........................................................................... 3
   II.A.1. Award History ................................................................................. 3
   II.B. Award Information ............................................................................. 3
   II.C. Eligibility Information ...................................................................... 7
   II.C.1. Eligible Applicants ......................................................................... 7
   II.C.2. Cost Sharing .................................................................................. 8
   II.C.3. Other ............................................................................................. 8
   II.D. Application and Submission Information ........................................ 8
   II.D.1. Address to Request Application Package ...................................... 8
   II.D.2. Content and Form of the Application Submission ......................... 9
   II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM) ..... 28
   II.D.4. Submission Dates and Times ......................................................... 29
   II.D.5. Funding Restrictions .................................................................... 30
   II.D.6. Other Submission Requirements ................................................... 31
   II.E. Application Review Information .................................................... 31
   II.E.1. Criteria .......................................................................................... 31
   II.E.2. Application Review and Selection Process .................................... 35
   II.E.3. Integrity and Performance Information ......................................... 36
   II.E.4. Anticipated Announcement and Federal Award Dates .................. 36
   II.F. Federal Award Administration Information .................................... 36
   II.F.1. Federal Award Notices .................................................................. 36
   II.F.2. Administrative and National Policy Requirements ....................... 37
   II.F.3. Reporting ....................................................................................... 38
   II.G. Federal Awarding Agency Contacts .............................................. 38
   II.G.1. CDMRP Help Desk ...................................................................... 38
   II.G.2. Grants.gov Contact Center ........................................................... 38
   II.H. Other Information ........................................................................... 39
   II.H.1. Program Announcement and General Application Instructions Versions .......... 39
   II.H.2. Administrative Actions .................................................................. 39
   II.H.3. Application Submission Checklist ................................................. 42

APPENDIX 1: ACRONYM LIST ...................................................................... 44
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

*New for 2018:* Application submission by extramural organizations through Grants.gov requires use of the Workspace interface, which separates the application package into individual forms. Applicants must create a Workspace in Grants.gov, complete the required forms, and submit their application Workspace package.

II.A. Program Description

Applications to the Fiscal Year 2018 (FY18) Epilepsy Research Program (ERP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The ERP was initiated in FY15 to develop an understanding of the magnitude of post-traumatic epilepsy (PTE) within the military, and to expand research into the basic mechanisms by which traumatic brain injury (TBI) produces PTE. These are reflected in the ERP’s vision and mission:

**Vision:** The ERP envisions a time when the causative links between TBI and epilepsy are understood and PTE is both preventable and treatable.

**Mission:** The ERP’s mission is to advance research to understand the mechanisms underlying the genesis and progression of PTE, especially in Service members and Veterans.

Appropriations for the ERP from FY15 through FY17 totaled $22.5 million (M). The FY18 appropriation is $7.5M.

II.A.1. Award History

The ERP Longitudinal Risk Factors Award (LRFA) mechanism is being offered for the first time in FY18.

II.B. Award Information

The intent of the FY18 ERP LRFA is to support a large-scale, prospective, longitudinal epidemiological research study that is relevant to the characterization of PTE. The work must be related to the ERP’s mission (see Section II.A, Program Description). Applications should describe how the association of TBI and subsequent PTE will be assessed or characterized. This would include a description of the nature of the TBIs in the cohort. Studies that evaluate the feasibility of using combinations of outcomes (e.g., neuropsychological assessments, imaging, and genomics) are encouraged. Therefore, interdisciplinary research teams or consortia are also encouraged. *Note that applicants will be required to submit a Preproposal Narrative.*
Due to the intent of this mechanism, preliminary data are required. In addition, expedited access to an already identified, suitable study cohort that will support the proposed hypothesis or hypotheses is required. As part of the application process, all applicants are required to provide a Longitudinal Studies Research Statement that addresses the longitudinal aspects of the project. Applicants will also be required to provide a statistical plan and identify appropriate personnel to support the statistical plan as part of the full application.

The anticipated direct costs budgeted for the entire period of performance for an FY18 ERP LRFA will not exceed $2.5M. The maximum period of performance is 4 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

The FY18 ERP LRFA is open to eligible applicants whose named Principal Investigators (PIs) are at or above the level of Assistant Professor (or equivalent) from any field or discipline.

**FY18 ERP LRFA Focus Area:** The research impact for the FY18 ERP LRFA is expected to benefit the military, Veteran, and civilian communities. To this end, applications must address the following FY18 ERP LRFA Longitudinal Studies Focus Area. An application that proposes research outside of the FY18 ERP LRFA Longitudinal Studies Focus Area is strongly discouraged.

- **Longitudinal Studies:** Studies of the natural evolution of post-traumatic epileptogenesis, which may include:
  - Seizure frequency and severity
  - Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
  - Latency between injury and PTE
  - Mortality
  - Treatment
  - Quality of life of individuals with PTE

*Note: This mechanism is not intended to fund animal research.*

*Note: Research focusing on interventional clinical trials (e.g., pharmacological interventions) is strongly discouraged.*

The types of awards made under the Program Announcement will be assistance agreements (grants or cooperative agreements). The level of involvement on the part of the Department of Defense (DoD) during project performance is the key factor in determining whether to award a grant or cooperative agreement.

**Extramural Organizations:** An assistance agreement (grant or cooperative agreement) is appropriate when the Federal Government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation.
authorized by a law of the United States, instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305) and the award will identify the specific substantial involvement. Substantial involvement may include collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DoD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB/EC. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Additional time for regulatory reviews may be needed for clinical studies taking place in international settings. When possible, protocols should be written for research with human subjects and/or human anatomical substances that are specific to the DoD-supported effort outlined in the submitted application as a stand-alone study. Submission to HRPO of protocols involving more than the scope of work in the DoD-funded award will require HRPO review of the entire protocol (DoD and non-DoD). DoD human subjects protection requirements may be applied to non-DoD-funded work and necessitate extensive revisions to the protocol. Refer to the General Application Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.

A clinical trial is defined as a prospective accrual of patients (human subjects) in whom an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction.

Use of DoD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active duty military patient populations and/or DoD resources or databases, the PI is responsible for demonstrating such access at the time of application submission and should develop a plan for maintaining access as needed throughout the proposed research. Access to target active duty military patient population(s) and/or DoD resource(s) or database(s) should be confirmed by including a letter of support, signed by the lowest-ranking person with approval authority.
If the proposed research involves access to VA patient populations, VA study resources and databases, and/or VA research space and equipment, VA PIs must have a plan for obtaining and maintaining access throughout the proposed research. Access to VA patients, resources, and/or VA research space should be confirmed by including a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief. If appropriate, the application should identify the VA-affiliated non-profit corporation (NPC) as the applicant institution for VA PIs. If the VA NPC is not identified as the applicant institution for administering the funds, the application should include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Access to certain DoD or VA patient populations, resources, or databases may only be obtained by collaboration with a DoD or VA investigator who has a substantial role in the research and may not be available to a non-DoD or non-VA investigator if the resource is restricted to DoD or VA personnel. Investigators should be aware of which resources are available to them if the proposed research involves a non-DoD or non-VA investigator collaborating with the DoD and/or VA. If access cannot be confirmed at the time of application submission, the Government reserves the right to withdraw or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resource(s). Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information.

Information Regarding Common Data Elements (CDEs) and Data Sharing

FITBIR Reporting Requirement for Projects Producing TBI Datasets: The DoD requires that awardees make TBI data generated via this award mechanism available to the research community by depositing de-identified research data into the Federal Interagency TBI Research (FITBIR) informatics system on a quarterly basis. The FITBIR informatics system is a free resource to the research community designed to accelerate comparative effectiveness research on brain injury diagnosis and treatment. Data reporting to FITBIR is an opportunity for investigators to facilitate their own research and to collaborate with others doing similar research. While there is no direct charge to users of the FITBIR informatics system, a project estimation tool (https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp) is available to help estimate costs and manpower needs that may be associated with data submission. To contribute to FITBIR, researchers should contact the FITBIR Operations Center ahead of time to arrange for data entry support and to ensure all data have been made compatible with the system. FITBIR guidance and policies, as well as the considerable advantages of FITBIR use to the researcher, are detailed at FITBIR: Federal Interagency Traumatic Brain Injury Research Informatics System (http://fitbir.nih.gov/).

FITBIR allows for de-identification and storage of data (medical imaging clinical assessment, environmental and behavioral history, etc.) of various types (text, numeric, image, time series, etc.). Use of FITBIR’s Global Unique Identifier (GUID) system facilitates repeated and multi-user access to data without the need to personally identify data sources. FITBIR encourages collaboration between laboratories, as well as interconnectivity with other informatics platforms. Such community-wide sharing requires common data definitions and standards.
Use of TBI CDEs: Data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI CDEs or entered into the FITBIR data dictionary as new, unique data elements. For the most current version of the NINDS TBI CDEs, go to http://www.commondataelements.ninds.nih.gov. Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs collected are compatible with the FITBIR informatics system. If the proposed research data cannot be entered in CDE format, the investigators must supply a proposal for an alternative data submission or data-sharing vehicle and justification for use. Use of the TBI CDEs is required wherever possible in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical studies of TBI.

Note: In addition to the TBI CDEs, applicants are also strongly encouraged to consider developing a plan to incorporate the NINDS CDEs for epilepsy found at the link above.

The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.

Awards will be made no later than September 30, 2019. For additional information refer to Section II.F.1, Federal Award Notices.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and Federal Government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this Program Announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DoD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, Government, and research institutes.

Intramural DoD Organization: A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center.

Note: Applications from an intramural DoD organization or from an extramural Federal organization may be submitted through a research foundation.
The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at http://orcid.org/.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

Each investigator may be named in only one FY18 ERP LRFA application as a PI.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this Program Announcement.

II.D. Application and Submission Information

*Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).*

*Extramural Submission* is defined as an application submitted by an organization to Grants.gov.

*Intramural DoD Submission* is defined as an application submitted by a DoD organization to eBRAP.

II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications
and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

**Extramural Submissions:** Pre-application content and forms must be accessed and submitted at eBRAP.org. Full application packages must be accessed and submitted at Grants.gov.

**Intramural DoD Submissions:** Pre-application content and forms and full application packages must be accessed and submitted at eBRAP.org.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

### II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both *pre-application* and *full application* as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods.

**Pre-Application Submission:** All pre-applications for both extramural and intramural organizations must be submitted through eBRAP ([https://eBRAP.org/](https://eBRAP.org/)).

**Full Application Submission:** Full applications must be submitted through the online portals as described below.

**Submitting Extramural Organizations:** Full applications from extramural organizations must be submitted through a Grants.gov Workspace. Applications submitted by extramural organizations (e.g., research foundations) on behalf of intramural DoD or other Federal organizations or investigators will be considered extramural submissions. Applications from extramural organizations, including non-DoD Federal organizations, received through eBRAP will be withdrawn. See definitions in Section II.C.1, Eligible Applicants.

**Submitting Intramural DoD Organizations:** Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Intramural DoD organizations that are unable to submit to Grants.gov should submit through eBRAP. Intramural DoD organizations with the capability to submit through Grants.gov may submit following the instructions for extramural submissions through Grants.gov or may submit to eBRAP.

**For Both Extramural and Intramural Applicants:** A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the full application submissions associated with them. eBRAP will validate full application files against the specific Program Announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement.

*The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process.* Inconsistencies may delay
application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, each submission is assigned a unique log number by eBRAP. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. Incorrect selection of extramural or intramural submission type will delay processing.

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**
  
  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Note that the codes have recently been revised. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**
  
  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 (R&R) Form). The Business Official must
be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 (R&R) Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

FY18 ERP Programmatic Panel members should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in pre-application or application preparation, research, or other duties for submitted pre-applications or applications. For FY18, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Pre-applications or applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage conflicts of interest (COIs) are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship). Refer to the General Application Instructions, Appendix 3, Section C, for further information regarding COIs.

- **Tab 5 – Pre-Application Files**

*Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an
unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- A description of how the pre-application meets the intent of the FY18 ERP LRFA mechanism (see Section II.B, Award Information).

- A description of how the research is aligned with the FY18 ERP LRFA Longitudinal Studies Focus Area (see Section II.A.1, FY18 ERP LRFA Focus Area). An application that proposes research outside of the Longitudinal Studies Focus Area is strongly discouraged.

- A description of the proposed scientific hypothesis (or hypotheses) and rationale.

- Relevant preliminary data. Preliminary data can come from the PI’s published work, pilot data, or from peer-reviewed literature.

- Evidence of expedited access to an already identified, suitable study cohort that will support the proposed hypothesis or hypotheses.

*Note: This mechanism is not intended to fund animal research.*

*Note: Research focusing on interventional clinical trials (e.g., pharmacological interventions) is strongly discouraged.*

○ **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:

  - References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).

  - List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

  - Key Personnel Biographical Sketches (five-page limit per individual). *All biographical sketches should be uploaded as a single combined file.* Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- **Tab 6 – Submit Pre-Application**

  This tab must be completed for the pre-application to be accepted and processed.
Pre-Application Screening

- Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the ERP, pre-applications will be screened based on the following criteria:

  o Does the pre-application meet the intent of the FY18 ERP LRFA mechanism?
  o Does the pre-application identify and align with the FY18 ERP LRFA Longitudinal Studies Focus Area?
  o What are the merits of the scientific hypothesis (or hypotheses) and rationale as they pertain to the mission of the ERP?
  o Are the preliminary data supportive of the proposed hypothesis (or hypotheses) and rationale?
  o Does the pre-application demonstrate evidence of access to an identified patient cohort?
  o Are the qualifications of the PI and key personnel appropriate?
  o Does the study team demonstrate expertise in both TBI and epilepsy?

- Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in Section I, Overview of the Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

II.D.2.b. Step 2: Full Application Submission Content

Applications will not be accepted unless the PI has received notification of invitation.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this Program Announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (http://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.
II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in the Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the **same version** of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov ([https://www.grants.gov/web/grants/applicants/apply-for-grants.html](https://www.grants.gov/web/grants/applicants/apply-for-grants.html)) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

**Table 1. Full Application Submission Guidelines**

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td></td>
</tr>
<tr>
<td>Download application package components for W81XWH-18-ERP-LRFA from Grants.gov (<a href="http://www.grants.gov">http://www.grants.gov</a>) and create a Grants.gov Workspace. The Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</td>
<td>Download application package components for W81XWH-18-ERP-LRFA from eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SF424 (R&amp;R) Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
</tbody>
</table>
### Extramural Submissions

Descriptions of each required file can be found under Full Application Submission Components:

- **Attachments**
- **Research & Related Personal Data**
- **Research & Related Senior/Key Person Profile (Expanded)**
- **Research & Related Budget**
- **Project/Performance Site Location(s) Form**
- **R&R Subaward Budget Attachment(s) Form** (if applicable)

### Intramural DoD Submissions

**Tab 3 – Full Application Files:** Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:

- **Attachments**
- **Key Personnel**
- **Budget**
- **Performance Sites**

**Tab 4 – Application and Budget Data:** Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.

### Application Package Submission

**Create a Grants.gov Workspace.**

Add participants (investigators and Business Officials) to the Workspace, complete all required forms, and check for errors before submission.

**Submit a Grants.gov Workspace Package.**

An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package **at least 24-48 hours prior to the close date** to allow time to correct any potential technical issues that may disrupt the application submission.

**Note:** If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.

**Submit package components to eBRAP (https://ebrap.org).**

**Tab 5 – Submit/Request Approval Full Application:** After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email.
Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. *The Project Narrative and Budget cannot be changed after the application submission deadline.* Prior to the full application deadline, a corrected or modified full application package may be submitted. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

*Material submitted after the end of the application verification period, unless specifically requested by the Government, will not be forwarded for processing.*

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DoD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Verification Period</strong></td>
<td></td>
</tr>
<tr>
<td>The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, <em>with the exception of the Project Narrative and Budget Form</em>, may be modified.</td>
<td>After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, <em>with the exception of the Project Narrative and Budget Form</em>, may be modified. Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.</td>
</tr>
<tr>
<td><strong>Further Information</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Tracking a Grants.gov Workspace Package.</strong> After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.</td>
<td>Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.</td>
</tr>
</tbody>
</table>
II.D.2.b.ii. Full Application Submission Components

- **Extramural Applications Only**

  **SF424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

  **Attachments:**

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf.”

    The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

    Describe the proposed project in detail using the outline below.

    - **Background:** Present the ideas and reasoning behind the proposed research; include relevant literature citations. Describe previous experience most pertinent to this application. This section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses.

    - **Preliminary Data:** Provide preliminary data to support the rationale and feasibility of the study. Preliminary data may come from PI’s published work, pilot data, or from peer-reviewed literature.

    - **Hypothesis (or Hypotheses):** State the hypothesis (or hypotheses) to be tested.

    - **Specific Aims:** Concisely explain the project’s specific aims.

    - **Project Milestones:** Concisely provide expected project milestones relevant to each of the project’s technical objectives and specific aims.
Research Strategy and Data Analysis: Describe the experimental design, study outcomes, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Provide details regarding the nature of the study cohort, and its suitability to the proposed study. Include a detailed plan for the recruitment of subjects and the acquisition of samples. Include a description of the nature of the TBIs in the cohort. Specify the approximate number of human subjects to be enrolled. Applications should describe how the association of TBI and subsequent PTE will be assessed or characterized. Describe the plans to collect specimens (if applicable) and conduct laboratory evaluations (if applicable), and the types of data collection instruments (if applicable). Address potential problem areas and present alternative methods and approaches. Include a description of the logistical aspects (e.g., communication plan, data transfer and management, standardization of procedures) of the study.

Statistical Plan: Clearly describe the statistical plan and the rationale for the statistical methodology as well as an appropriate power analysis.

Note: This mechanism is not intended to fund animal research.

Note: Research focusing on interventional clinical trials (e.g., pharmacological interventions) is strongly discouraged.

Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf.” Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under
which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents**: Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support** (three-page limit per letter): Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration** (if applicable) (three-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.


  - **Intellectual and Material Property Plan** (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

  - **Commercialization Strategy** (if applicable): Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- **Use of DoD Resources** (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military patient populations and/or DoD resources or databases.

- **Use of VA Resources** (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the ACOS/R&D or Clinical Service Chief confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA NPC is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.
Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf.” The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Describe the proposed research project including the following elements:

- **Background:** Present the ideas and reasoning behind the proposed project.
- **Hypothesis (or Hypotheses):** State the hypothesis (or hypotheses) to be tested.
- **Specific Aims:** Concisely explain the project’s specific aims.
- **Research Strategy:** Briefly describe the research strategy.

Of particular importance, programmatic reviewers typically do not have access to the full application and therefore rely on the technical abstract for appropriate description of the project’s key aspects. Therefore, clarity and completeness within the space limits of the technical abstract are highly important.

Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf.” The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Describe the scientific objective and rationale for the proposed project in a manner that will be readily understood by readers without a background in science or medicine.

Of particular importance, programmatic reviewers typically do not have access to the full application and therefore rely on the lay abstract for appropriate description of the project’s key aspects. Therefore, clarity and completeness within the space limits of the lay abstract are highly important.

Attachment 5: Statement of Work (SOW) (five-page limit): Upload as “SOW.pdf.” The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the LRFA mechanism, use the SOW format example titled “SOW for Clinical Research (Including Trials, Special Populations).” The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:
Include the name(s) of the key personnel and contact information for each study site/subaward site.

Indicate the number (and type, if applicable) of research subjects (human) and/or human anatomical samples projected or required for each task and at each site. Refer to the General Application Instructions, Appendix 1, for additional information regarding regulatory requirements.

For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.

If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., Investigational Device Exemption applications) by the U.S. Food and Drug Administration (FDA) or other Government agency.

Briefly state the methods to be used.

If human anatomical substances (including cell lines) will be used, specify whether or not identifiable information is accessible to the research team by any means.


- **Study Population:** Describe the cohort (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site (population from whom the sample will be recruited/drawn). Demonstrate that the research team has expedited access to the proposed study population. Furthermore, discuss past efforts in recruiting human subjects from the target population. Address any potential barriers to accrual and plans for addressing unanticipated delays. Include justification of any age, race, ethnicity, or sex limitations provided.

- **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed research. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

- **Inclusion of Women and Minorities in Study:** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the proposed research.
- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, health care provider identification).

  - Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
  
  - Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
  
  - Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

- **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.

  - For the proposed study, provide a draft, in English, of the Informed Consent Form.
  
  - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the trial.
  
  - Include information regarding the timing and location of the consent process.
  
  - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
  
  - Address how privacy and time for decision-making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
  
  - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.
  
  - Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed study to be in compliance with 10 USC 980 (http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf). If
applicable, please refer to the General Application Instructions, Appendix 1, for more information.

- **Assent.** If minors or other populations that cannot provide informed consent are included in the proposed study, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Please note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.

- **Risks/Benefits Assessment**
  - **Foreseeable Risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is subjected to as a result of participation in the proposed study. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

  o **Attachment 7: Study Personnel and Organization (no page limit):** Start each document on a new page. Combine into one document and upload as “Personnel.pdf.” The Study Personnel and Organization attachment should include the components listed below.

    - **Organizational Chart:** Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers, and/or departments and name each person’s position on the project. Include any separate laboratory or testing centers. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, as appropriate. Identify and provide justification for the inclusion of international sites, as appropriate.

    - **Study Personnel Description:** Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role.

    - **Study Management Plan:** Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed study is multi-institutional, clearly describe the multi-institutional structure governing the research protocol(s) across all participating institutions. If applicable, describe how communication and data transfer between the collaborating institutions will occur, as
well as how data, specimens, and/or imaging products obtained during the study will be handled and shared.

○ Attachment 8: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit): Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study. Describe how and when the instrument(s) will be administered. Describe how the instrument(s) will be adapted to the subject population, if applicable.

○ Attachment 9: Impact Statement (one-page limit): Upload as “Impact.pdf.” Detail the anticipated outcome(s) that will be directly attributed to the results of the proposed research (short-term gains). Explain the anticipated long-term gains from the proposed research project. Furthermore, detail how the research efforts will address the ERP’s mission, and ultimately benefit individuals affected by epilepsy, their caregivers, and their families (see Section II.A, Program Description). The application must include an Impact Statement.

○ Attachment 10: Focus Area Statement (one-page limit): Upload as “FAS.pdf.” Describe how the application addresses the FY18 ERP LRFA Longitudinal Studies Focus Area (see Section II.B, Award Information) and its relevance. An application that proposes research outside of the FY18 ERP LRFA Longitudinal Studies Focus Area is strongly discouraged. The application must include a Focus Area Statement.

○ Attachment 11: Data Management (no page limit): Upload as “Data_Manage.pdf.” The Data Management attachment should include the components listed below.

  – Data Management: Describe all methods used for data collection to include the following:

    ▪ Identifiers: Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.

    ▪ Confidentiality

      ✓ Explain measures taken to protect the privacy of study human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.

      ✓ Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of USAMRMC are eligible to review study records.

      ✓ Address requirements for reporting sensitive information to state or local authorities.
- **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.

- **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

---

## Laboratory Evaluations

- **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

- **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

- **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

- **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

---

○ **Attachment 12: Data and Research Resource Sharing Plan (two-page limit):**

  Upload as “Sharing.pdf.” Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available. A robust plan is required as part of the application process. Describe the type of data or research resource to be made publicly available as a result of the proposed work. Also, describe the plan for the provision of access to the data or research resource generated from the proposed work to the public and how the data or resource will be made available after the award expires. Provide a milestone plan for data dissemination as part of this statement.
Applications that include studies of TBI must consider the following as part of the Data Sharing and Research Resource Plan:

- **Use of TBI Common Data Elements:** If an applicant’s study involves the generation of TBI datasets, the applicant must describe how he/she will use the NINDS TBI CDEs (see [http://www.commondataelements.ninds.nih.gov](http://www.commondataelements.ninds.nih.gov)). If the proposed research is not compatible with the required CDEs, the applicant should supply justification why these measures will not be incorporated into the research.

  **Note:** In addition to the TBI CDEs, applicants are also strongly encouraged to consider developing a plan to incorporate the NINDS CDEs for epilepsy found at the link above.

- **FITBIR Reporting Requirement:** A plan for reporting to the FITBIR ([https://fitbir.nih.gov](https://fitbir.nih.gov)) data repository must also be described in the Data and Research Resource Sharing Plan, if applicable. If the proposed study is not compatible with the database, the applicant should supply a justification for not using the database. Applicants should review the FITBIR guidance regarding the inclusion of costs in the proposed budget associated with reporting to FITBIR.

  **For additional guidance regarding sharing of data and research resources, refer to the General Application Instructions, Appendix 2, Section K.**

- **Attachment 13: Longitudinal Studies Research Statement (two-page limit):** Upload as “Epi.pdf.” Applications must address how the study will conduct research in accordance with the 2011 International League Against Epilepsy research guidelines found at [http://www.ncbi.nlm.nih.gov/pubmed/21899536](http://www.ncbi.nlm.nih.gov/pubmed/21899536). Applications must address the longitudinal aspects of these guidelines in accordance with the FY18 ERP Longitudinal Studies Focus Area. The application must include a Longitudinal Studies Research Statement.

- **Attachment 14: Representations (extramural submissions only):** Upload as “MandatoryReps.pdf.” All extramural applicants must complete and submit the Required Representations template available on eBRAP ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

- **Attachment 15: DoD Military Budget Form(s), if applicable:** Upload as “MFBudget.pdf.” If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the DoD Military Budget Form, available for download on the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs. Refer to the General Application Instructions, Section III.A.7, for detailed information.
Extramural and Intramural Applications

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC A§1681 et seq.), the DoD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

○ PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in the PDF format that is not editable.

○ PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

○ Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf.”

○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf.” The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.
• Extramural Applications Only

R&R Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.6, for detailed information.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.6, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

Intramural DoD Collaborator(s): Complete the DoD Military Budget Form and upload to Grants.gov attachment form as Attachment 15. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Intramural DoD Collaborator(s) costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs.

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant’s organization’s Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

New Requirement: In March 2018, the General Services Administration (GSA) implemented fraud prevention security measures in the System for Award Management (SAM) which required every new contractor registrant to provide a written (hard copy), notarized letter confirming the entity’s Administrator that is authorized to register the entity in the SAM database, or to make changes to its registration. Effective 29 April 2018, the notarized letter process is now mandatory on all CURRENT registrants at SAM who have a requirement to update data on their SAM record. The notarized letter is mandatory and is required before the GSA Federal Service Desk (FSD) will activate the entity’s registration. The Office of the Secretary of Defense and GSA realizes the length of time needed to transmit, receive, process, and approve the notarized letters presents a significant impact on the ability of the contracting activity to make timely awards, but in order to mitigate the concern of fraud, these steps and the time needed for processing, is unavoidable. Notarized letters are required for all new and existing SAM registered Entities. The notarized letters must be postal service mailed (not emailed or faxed) to the “Federal Service Desk” and must contain the information outlined in the SAM posted FAQ at: (https://www.gsa.gov/about-us/organization/federal-acquisition-service/office-of-systems-management/integrated-award-environment-iae/sam-update). Instructions for domestic entities
and instructions for international entities with embedded templates for use are also provided within the SAM Update notice with frequently asked questions at https://www.gsa.gov/about-us/organization/federal-acquisition-service/office-of-systems-management/integrated-award-environment-iae/sam-update.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate retrieved files against the specific Program Announcement requirements and discrepancies will be noted in both the email and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Budget Form cannot be changed after the application submission deadline.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

Intramural DoD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.
II.D.5. Funding Restrictions

The maximum period of performance is 4 years.

The anticipated direct costs budgeted for the entire period of performance will not exceed $2.5M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $2.5M direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

For this award mechanism, direct costs may be requested for (not all-inclusive):

- Salary
- Research-related supplies and subject costs
- Preclinical research costs
- Subject reimbursement and compensation
- Support for multidisciplinary collaborations
- Data and research resource sharing costs associated with the execution of the Data and Research Resource Sharing Plan
- Travel costs for one investigator to travel to two scientific/technical meetings per year to present project outcomes from the ERP LRFA.

Awards made to extramural organizations will consist solely of assistance agreements (grants and cooperative agreements). For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct fund transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.4, for budget regulations and instructions for the Research & Related Budget. For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.4.
The CDMRP expects to allot approximately $4M of the $7.5M FY18 ERP appropriation to fund approximately one LRFA application, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement is contingent upon the availability of Federal funds for this program.

Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. The time is considered when establishing the award’s period of performance. It is anticipated that awards made from this funding opportunity will be funded with FY18 funds, which will expire for use on September 30, 2024.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in decreasing order of importance:

- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, relevant preliminary data, and/or logical reasoning.
  - How well the hypothesis (or hypotheses) or objectives, study outcomes, aims, experimental design, methods, and analyses are developed.
  - How well the choice of study variables is justified as they pertain to the study’s hypothesis (or hypotheses).
  - How well the project’s milestones support the accomplishment of the project’s objectives and specific aims.
  - How well the application captures the nature of the study cohort, and its suitability to the proposed study.
  - How well the application describes of the nature of the TBIs in the cohort.
  - How well the application describes how the association of TBI and subsequent PTE will be assessed or characterized.
○ How well plans to collect specimens and conduct laboratory evaluations are addressed, if applicable.

○ To what degree the data collection instruments (e.g., surveys, questionnaires), if applicable, are appropriate to the proposed study.

○ How well the logistical aspects of the proposed study (e.g., communication plan, data transfer and management, standardization of procedures) meet the needs of the proposed study.

○ How well the application acknowledges potential problems and addresses alternative approaches.

• Statistical Plan

○ To what degree the statistical model and data analysis plan are suitable for the planned study.

○ To what degree the statistical plan, including sample size projections and power analysis, is adequate for the study and all proposed correlative studies.

○ To what degree the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

• Recruitment, Accrual, and Feasibility

○ How well the application addresses the availability of human subjects for the proposed study and the prospect of their participation.

○ How well the study cohort is described and its suitability to the proposed study.

○ Whether the application has demonstrated expedited access to the proposed human subjects population.

○ The degree to which the recruitment, informed consent, screening, and retention processes for human subjects will meet the needs of the proposed study.

○ How well the application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.

○ To what extent the proposed study might affect the daily lives of the individual human subjects participating in the study (e.g., Will human subjects still be able to take their regular medications while participating in the study? Are human subjects required to stay overnight in a hospital?).

○ How well the inclusion and exclusion criteria meet the needs of the study.

○ To what degree privacy and confidentiality issues are appropriately considered.
○ To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.

○ How well the study identifies all risks, including potential safety concerns and adverse events.

**Personnel**

○ How well the applicant shows potential for addressing the ERP’s mission (see Section II.A, Program Description) based on his/her background and experience.

○ How well the study team’s background and related expertise are appropriate with respect to its ability to perform the proposed work.

○ To what extent the composition of the study team, to include the applicant, is appropriate and includes expertise in both TBI and epilepsy.

○ To what degree the levels of effort are appropriate for successful conduct of the proposed work.

○ How well the roles of the study team are delineated to include an outline of the governing structure.

○ How well the plan for ensuring the standardization of procedures among staff and across sites is developed (if applicable).

**Impact**

○ Assuming the objectives/goals of the proposed research are realized, to what extent:
  
  – The anticipated outcomes (short-term) will be used as the foundation for future research projects.

  – The anticipated long-term scientific gains will contribute to the goal of achieving the ERP’s mission (see Section II.A, Program Description).

  – The efforts will ultimately benefit individuals affected by epilepsy, their caregivers, and their families.

**Focus Area**

○ How well the proposed study addresses the FY18 ERP LRFA Longitudinal Studies Focus Area.

○ How relevant the proposed research is to the FY18 ERP LRFA Longitudinal Studies Focus Area.
• **Longitudinal Studies Research**

• **Data Management**
  ○ How well the methods used for data collection are described.
  ○ To what degree the data management plan is relevant to the proposed study.
  ○ How well human subjects’ privacy is protected.
  ○ How well the application describes the data capture and verification plans.

• **Data and Research Resource Sharing Plan**
  ○ To what degree the proposed plan for sharing data and research resources is appropriate, including but not limited to:
    – The description of the type of data or research resource to be made publicly available.
    – Ease of access for other researchers to the data or research resource.
    – The appropriateness of plans to ensure the data or research resource is accessible after the period of performance expires.
    – The appropriateness of the milestones with respect to making the data or research resource available.
    – The appropriateness of the FITBIR data sharing plan (if applicable).

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• **Budget**
  ○ Whether the **direct** maximum costs are equal to or less than the allowable **direct** maximum costs as published in the Program Announcement.
  ○ Whether the budget is appropriate for the proposed research.

• **Intellectual Property**
  ○ If applicable, to what degree the intellectual and material property plan is appropriate.
• Application Presentation
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.
  ○ How well the application reflects knowledge and respect for the needs of individuals, caregivers, and their families.

• Environment
  ○ To what degree the scientific environment is appropriate for the proposed research.
  ○ To what degree the quality and extent of organizational support are appropriate.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

• Ratings and evaluations of the peer reviewers

• Relevance to the mission of the DHP and FY18 ERP, as evidenced by the following:
  ○ Adherence to the intent of the award mechanism
  ○ Program portfolio composition
  ○ Relative impact

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. Each application is evaluated for its own merit, independent of other applications. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, USAMRMC, on behalf of the DHA and the OASD(HA), based on technical merit, the relevance to the mission of the DHP and ERP, the specific intent of the award mechanism, and to other specified evaluation criteria in the Program Announcement. Programmatic review is a comparison-based process in which applications with scientific and technical merit compete in a common pool. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement that application and evaluation
information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold (currently $150,000) over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under Federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards will be made no later than September 30, 2019. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from the USAMRAA will contact the business official authorized to negotiate on behalf of the PI’s organization.
Only an appointed USAMRAA Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document.

**Federal Organizations:** Awards to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

After email notification of application review results through eBRAP, and if selected for funding, a representative from the CDMRP will contact the business official authorized to negotiate on behalf of the PI’s organization.

**II.F.1.a. PI Changes and Award Transfers**

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer. An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

**II.F.2. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter 1, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this Program Announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.


Copies of all scientific publications and presentations as a result of this funding are required.
II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. **If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.**

Annual progress reports as well as a final progress report will be required.

Quarterly technical progress reports will be required.

In addition to written progress reports, in-person presentations may be requested.

Annual quad charts will be required.

Awards resulting from this Program Announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are required to disclose semiannually information about criminal, civil, and administrative proceedings as specified in the applicable Terms and Conditions (see General Application Instructions, Section III.A.4).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to Program Announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov
Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the Program Announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this Program Announcement should refer to the Program name, the Program Announcement name, and the Program Announcement version code 20180329g. The Program Announcement numeric version code will match the General Applications Instructions version code 20180329.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- More than one application is received with the same named PI. Only the first application received will be accepted; additional applications will be administratively rejected.
- Impact Statement (Attachment 9) is missing.
- Focus Area Statement (Attachment 10) is missing.
- Longitudinal Studies Research Statement is missing (Attachment 13)
II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.

- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY18 ERP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY18 ERP Programmatic Panel members can be found at http://cdmrp.army.mil/erp/panels/panels18.

- The application fails to conform to this Program Announcement description to the extent that appropriate review cannot be conducted.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY18, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage COIs are provided and deemed appropriate by the Grants Officer. Refer to the General Application Instructions, Appendix 3, for detailed information.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

- Applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.

- Applications submitted by an intramural DoD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

- Submission of the same research project to different funding opportunities within the same program and fiscal year.
• The invited application does not propose the same research project described in the pre-application.

• An application for which the PI does not meet the eligibility criteria will be withdrawn.

• Subaward budgets are missing (if applicable).

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
### II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 (R&amp;R) Application for Federal Assistance (Extramural submissions only)</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (Intramural submissions only)</td>
<td>Complete these tabs as instructed.</td>
<td></td>
</tr>
<tr>
<td><strong>Attachments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name “HumSubProc.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Personnel and Organization: Upload as Attachment 7 with file name “Personnel.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveys, Questionnaires, and Other Data Collection Instruments: Upload as Attachment 8 with file name “Surveys.pdf,” if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 9 with file name “Impact.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focus Area Statement: Upload as Attachment 10 with file name “FAS.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 11 with file name “Data_Manage.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data and Research Resource Sharing Plan: Upload as Attachment 12 with file name “Sharing.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal Studies Research Statement: Upload as Attachment 13 with file name “Epi.pdf.”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 14 with file name “MandatoryReps.pdf,” if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>DoD Military Budget Form(s):</td>
<td>Upload as Attachment 15 with file name “MFBudget.pdf,” if applicable.</td>
<td></td>
</tr>
<tr>
<td>Attach PI Biographical Sketch</td>
<td>(Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Attach PI Previous/Current/Pending Support</td>
<td>(Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Attach Biographical Sketch</td>
<td>(Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Attach Previous/Current/Pending Support</td>
<td>(Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (Extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Budget (Intramural submissions only)</td>
<td>Complete the DoD Military Budget Form and justification.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R&amp;R Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
<td></td>
</tr>
<tr>
<td>CDE</td>
<td>Common Data Element</td>
<td></td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
<td></td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
<td></td>
</tr>
<tr>
<td>COI</td>
<td>Conflict of Interest</td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>Defense Health Agency</td>
<td></td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
<td></td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
<td></td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
<td></td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
<td></td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
<td></td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
<td></td>
</tr>
<tr>
<td>ERP</td>
<td>Epilepsy Research Program</td>
<td></td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
<td></td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
<td></td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
<td></td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>FITBIR</td>
<td>Federal Interagency Traumatic Brain Injury Research</td>
<td></td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
<td></td>
</tr>
<tr>
<td>GUID</td>
<td>Global Unique Identifier</td>
<td></td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
<td></td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
<td></td>
</tr>
<tr>
<td>LAR</td>
<td>Legally Authorized Representative</td>
<td></td>
</tr>
<tr>
<td>LRFA</td>
<td>Longitudinal Risk Factors Award</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
<td></td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
<td></td>
</tr>
<tr>
<td>NINDS</td>
<td>National Institute for Neurological Disorders and Stroke</td>
<td></td>
</tr>
<tr>
<td>NPC</td>
<td>Non-Profit Corporation</td>
<td></td>
</tr>
<tr>
<td>OASD(HA)</td>
<td>Office of the Assistant Secretary of Defense for Health Affairs</td>
<td></td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
<td></td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
<td></td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td>PTE</td>
<td>Post-Traumatic Epilepsy</td>
<td></td>
</tr>
<tr>
<td>RDT&amp;E</td>
<td>Research, Development, Test, and Evaluation</td>
<td></td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
<td></td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
<td></td>
</tr>
<tr>
<td>STEM</td>
<td>Science, Technology, Engineering, Mathematics</td>
<td></td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic Brain Injury</td>
<td></td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
<td></td>
</tr>
<tr>
<td>USAMRMC</td>
<td>U.S. Army Medical Research and Materiel Command</td>
<td></td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
<td></td>
</tr>
<tr>
<td>VA</td>
<td>Department of Veterans Affairs</td>
<td></td>
</tr>
</tbody>
</table>